{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"9"}],"units":"Participants"}],"description":"This analysis includes the number of participants with AEs and serious AEs (SAEs) during the Treatment Period plus the Acute Follow-up (FU) Period (up to 30 days following last vaccination). An AE was defined as any unfavorable or unintended change in the structure, function or chemistry of the body temporally associated with the use of the product, whether or not considered related to the product, including any worsening of a preexisting condition which was temporally associated with the product. An SAE was defined as an AE resulting in death, was life-threatening, resulted in or prolonged hospitalization, was a congenital anomaly, a cancer, an overdose or other important medical event.","groups":[{"description":"Two IM injections of V935 low dose (LD), 1 given every other week over a 3-week period.","id":"OG000","title":"Part A: V935 LD"},{"description":"Three electroporation (EP) injections of V934 (LD) were administered, 1 given every other week over a 5-week period. Following a 4 week observation period, 2 IM injections of V935 (LD) were administered, 1 given every other week over a 3-week period.","id":"OG001","title":"Part A: V934 LD(3)+V935 LD"},{"description":"Two IM injections of V935 high dose (HD), 1 given very other week over a 3-week period.","id":"OG002","title":"Part A: V935 HD"},{"description":"Three EP injections of V934 (HD) were administered, 1 given every other week over a 5-week period. Following a 4 week observation period, 2 IM injections of V935 (HD) were administered, 1 given every other week over a 3-week period.","id":"OG003","title":"Part A: V934 HD(3)+V935 HD"},{"description":"Five EP injections of V934 (HD) were administered, 1 given every other week over a 9-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) were administered, 1 given every other week over a 3-week period.","id":"OG004","title":"Part A: V934 HD(5)+V935 HD"},{"description":"Participants who completed Part A could enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster were administered, 1 given every 2 weeks.","id":"OG005","title":"Part B: V935 LD/V934 Booster"},{"description":"Participants who completed Part A could enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster were administered, 1 given every 2 weeks.","id":"OG006","title":"Part B: V934 LD(3)+V935 LD/V934 Booster"},{"description":"Participants who completed Part A could enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster were administered, 1 given every 2 weeks.","id":"OG007","title":"Part B: V935 HD/V934 Booster"},{"description":"Participants who completed Part A could enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster were administered, 1 given every 2 weeks.","id":"OG008","title":"Part B: V934 HD(3)+V935 HD/V934 Booster"},{"description":"Participants who completed Part A could enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster were administered, 1 given every 2 weeks.","id":"OG009","title":"Part B: V934 HD(5)+V935 HD/V934 Booster"}],"paramType":"NUMBER","populationDescription":"All Participants as Treated (APaT) population; all participants who received at least one vaccination.","reportingStatus":"POSTED","timeFrame":"Day 1 up to 30 days following the last vaccination (up to 77 weeks); Treatment Period + Acute Follow-up (FU) Period","title":"Number of Participants With Adverse Events (AEs)","type":"PRIMARY","unitOfMeasure":"Participants"}